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Innate lymphoid cells (ILCs) reside primarily at barrier sur-
faces where they play key roles in maintaining mucosal ho-
meostasis and protecting against infection. Similar to CD4+ 
Th cells, ILCs can be grouped according to cytokine pro-
duction and transcription factor expression. For example, 
group 2 ILCs (ILC2s) express the transcription factor GATA3 
and produce the cytokines IL-5 and IL-13 in response to 
the epithelial cell–derived cytokines IL-25, IL-33, and thy-
mic stromal lymphopoietin, whereas ILC3s express RORγt 
and produce high levels of IL-17A, IL-17F, and IL-22 after 
stimulation with IL-23.
In adult mice, both ILC2s and ILC3s can develop from 
the common lymphoid progenitor (CLP) in the BM (Possot 
et al., 2011; Hoyler et al., 2012), which is followed develop-
mentally by a common helper-like ILC progenitor (ChILP) 
that expresses the transcription factor Id2 and the integrin 
α4β7 and responds to IL-7 (Moro et al., 2010; Cherrier et 
al., 2012; Klose et al., 2014). However, the mechanisms con-
trolling the lineage choice between ILC2s and ILC3s are un-
clear. ILC2 development is regulated by expression of several 
factors including TCF-1, Notch (Yang et al., 2013), RORα 
(Halim et al., 2012b; Wong et al., 2012), GATA3 (Hoyler et 
al., 2012), promyelocytic leukemia zinc finger protein (PLZF; 
Constantinides et al., 2014), and Gfi1 (Spooner et al., 2013). 
ILC3 development is mediated primarily through expres-
sion of the nuclear hormone receptor RORγt (Kurebayashi 
et al., 2000; Sun et al., 2000; Eberl et al., 2004; Sanos et 
al., 2009; Satoh-Takayama et al., 2010), although a role for 
GATA3 in ILC3 development has also been shown (Seraf-
ini et al., 2014; Yagi et al., 2014). Furthermore, recent studies 
demonstrated that Gfi1 (Spooner et al., 2013) and Bcl11b 
(Califano et al., 2015) are required to repress a subset of ILC3- 
specific genes, including Ahr, Rorc, Il17a, and Il17f. Thus, 
ILC2 and ILC3 developmental programs are intimately 
linked, and repression of one subset may be required to allow 
the development of the other.
G9a (Ehmt2 and Kmt1c) is a lysine methyltransferase 
that is responsible for the dimethylation of lysine 9 of histone 
H3 (H3K9me2; Tachibana et al., 2002). Studies in embryonic 
stem cells have demonstrated that G9a-dependent H3K9me2 
is required for gene silencing and is acquired at lineage- 
promiscuous genes as cells differentiate (Wen et al., 2009; 
Chen et al., 2012). However, we recently demonstrated that 
G9a is dispensable for lineage-promiscuous gene silenc-
ing in Th cells and that G9a, but not its methyltransferase 
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activity, is required for promoting Th2 cell differentiation 
(Lehnertz et al., 2010; Antignano et al., 2014). Based on the 
similarities between Th cells and ILCs, we sought to define 
the role of G9a in ILCs.
Here, we show that G9a is a cell-intrinsic regulator of 
ILC2 development, differentiation, and function. Loss of G9a 
or inhibition of its methyltransferase activity resulted in a loss 
of repression of the ILC3 lineage, expression of ILC3-associ-
ated genes, and increased numbers of ILC3s in the periphery. 
In WT immature ILC2s (iILC2s), repressive H3K9me2 marks 
were found at high levels at ILC3-associated genes but at 
low levels at the promoters of the actively transcribed ILC2- 
specific genes Il5 and Il13. Thus, the results presented here 
provide the first evidence of an epigenetic regulatory path-
way in ILC2s and identifies G9a-dependent H3K9me2 as a 
critical repressive mechanism to regulate ILC2 development.
RES ULTS AND DIS CUS SION
G9a regulates ILC2 development
To study the role of G9a in ILC development, we gener-
ated mice with a hematopoietic cell–specific deletion of 
G9a (termed Vav.G9a−/− mice) by crossing mice with a 
floxed allele of G9a (G9afl/fl mice; Lehnertz et al., 2010) 
with mice expressing Cre recombinase under the control 
of the Vav promoter. We analyzed the generation of iILC2s 
in the BM during steady-state hematopoiesis by flow cy-
tometric analysis of Lin− c-kitlow Sca-1high CD25+ CD127+ 
cells (Halim et al., 2012b; Hoyler et al., 2012). Despite 
having a significant expansion of Lin− c-kitlow Sca-1high 
cells, we found a significant reduction in the frequency of 
iILC2s in the BM of Vav.G9a−/− mice compared with con-
trol G9afl/fl mice (Fig. 1 A). During development from a 
CLP to iILC2, receptors for the cytokines IL-33 (ST2 and 
Il1rl1) and IL-25 (IL-17RB) are up-regulated (Halim et al., 
2012b; Wong et al., 2012; Constantinides et al., 2014). We 
found that iILC2s from G9afl/fl mice expressed high levels 
of ST2, whereas only ∼50% of iILC2s from Vav.G9a−/− mice 
expressed ST2 (Fig. 1 A), resulting in a 75% reduction in 
the number of Lin− c-kitlow Sca-1high CD25+ CD127+ ST2+ 
iILC2s in the absence of G9a (Fig. 1 B). In contrast to ST2, 
IL-17RB was expressed at equivalent levels by iILC2s from 
both G9afl/fl and Vav.G9a−/− mice (Fig. 1 C). In addition, 
BM iILC2s have been found to express the transcription 
factor GATA3 (Hoyler et al., 2012). We found that nearly 
all G9afl/fl Lin− c-kitlow Sca-1high CD25+ CD127+ cells 
expressed GATA3, but in the absence of G9a, only the 
ST2+ cells expressed GATA3 (Fig. 1 D). Systemic admin-
istration of IL-33 results in an expansion of ILC2s in the 
BM (Spooner et al., 2013). In response to IL-33, control 
G9afl/fl mice showed a significant increase in the number 
of BM iILC2s, whereas treatment with IL-33 failed to in-
duce comparable ILC2 development in the BM of Vav.
G9a−/− mice (Fig. 1 E). Thus, G9a plays an important role 
in ILC2 development, potentially through the regulation 
of IL-33 responsiveness.
To determine whether G9a functioned in a cell-au-
tonomous manner in regulating the development of ILC2s, 
we reconstituted lethally irradiated CD45.1+ mice with 
mixed BM harvested from congenic WT (CD45.1/2+) mice 
and CD45.2+ G9afl/fl or Vav.G9a−/− mice. Although a 50:50 
mix of donor BM (WT/G9afl/fl) yielded chimeric recipient 
mice with an ∼50:50 ratio of donor-derived hematopoietic 
cells, a 20:80 ratio of donor BM (WT/Vav.G9a−/−) was re-
quired to achieve comparable chimerism. Furthermore, de-
spite transplanting four times as many BM cells from Vav.
G9a−/− CD45.2+ mice, the G9a-deficient BM failed to give 
rise to iILC2s (Fig.  1, F and G). As Vav.Cre deletes early 
during hematopoiesis, it remains to be determined at what 
stage during ILC development G9a becomes important. We 
found that the absence of G9a does not affect the number 
of BM CLPs, but ChILPs and α4β7+ lymphoid progenitors 
(αLPs) were both reduced in the absence of G9a (Fig. 1 H), 
suggesting that G9a is important for differentiation of ILC 
progenitors downstream of the CLP.
G9a regulates peripheral ILC2 responses
ILC2s have been shown to be an important innate source 
of type 2 cytokines in the mesenteric LNs (mLNs; Neill et 
al., 2010), the lungs (Halim et al., 2012a), and visceral adi-
pose tissue (VAT; Moro et al., 2010). We found that Vav.G9a−/− 
mice have significantly fewer ILC2s in the mLNs, lungs, 
and VAT (Fig. 2, A and B) compared with G9afl/fl mice, but 
unlike in the BM, those that were present in the periphery 
expressed comparable levels of ST2 (Fig.  2  C). Thus, it is 
likely that the small number of ST2+ iILC2s in the BM of 
Vav.G9a−/− mice that were able to express GATA3 (Fig. 1 D) 
populated the peripheral tissues, albeit at significantly lower 
levels than G9afl/fl mice.
G9a regulates ILC2 function during lung inflammation
Treatment of mice intranasally with the protease papain has 
been shown to induce ILC2-dependent IL-5 and IL-13 
production, eosinophilia, and lung inflammation (Oboki et 
al., 2010; Halim et al., 2012a). After a short course of pa-
pain treatment, Vav.G9a−/− mice had reduced expression of 
Il5 and Il13 in the lungs and significantly reduced influx 
of eosinophils into the bronchoalveolar lavage (BAL) fluid 
compared with control G9afl/fl mice, despite equivalent eo-
sinophil numbers in the steady state (Fig. 3 A). In addition, 
after papain treatment of Vav.G9a−/− mice on a Rag1−/− 
background (Rag.Vav.G9a−/−), we observed significantly 
reduced eosinophilic influx into the BAL fluid compared 
with Rag.G9afl/fl mice (Fig. 3 B). After a longer course of 
papain administration (Spooner et al., 2013; Halim et al., 
2014), we found that Vav.G9a−/− mice had significantly 
fewer ILC2s and eosinophils in the lungs than control G9afl/
fl mice (Fig. 3 C). Thus, G9a controls ILC2 function during 
papain-induced lung inflammation.
We have recently shown that ILC2s facilitate the local 
development of a Th2 cell response in the house dust mite 
1155JEM Vol. 213, No. 7
(HDM) model of allergic lung inflammation (Gold et al., 
2014). Similar to results with papain, we found that num-
bers of ILC2s in the lungs as well as numbers of eosino-
phils in the BAL fluid of Vav.G9a−/− mice were significantly 
reduced compared with G9afl/fl mice (Fig.  3  D). Expres-
sion of Il5 and Il13 was also reduced in the lungs of Vav.
G9a−/− mice (Fig.  3  E). Consistent with these results, we 
observed significantly reduced goblet cell hyperplasia in the 
lungs of HDM-treated Vav.G9a−/− mice (Fig. 3, F and G). 
As numbers of ILC2s are reduced in the absence of G9a, we 
also wanted to determine whether the remaining ILC2s are 
functionally competent. To test this, we sorted equivalent 
numbers of mature ILC2s from the lungs of naive G9afl/fl 
and Vav.G9a−/− mice and stimulated them with IL-33 and 
thymic stromal lymphopoietin (Halim et al., 2012a). We 
found a significant reduction in IL-5 and IL-13 produc-
tion (Fig. 3 H), highlighting a role for G9a in promoting 
ILC2-dependent gene expression in mature ILC2s. Thus, 
these results demonstrate that G9a is a critical regulator of 
ILC2-dependent lung inflammation. 
Figure 1. G9a regulates the development of iILC2s. (A) Frequencies of iILC2s in G9afl/fl and Vav.G9a−/− mice. The numbers show percentages of gated 
cells (n > 12). (B) Absolute numbers of iILC2s in BM (n = 12 mice per genotype). (C) IL-17RB expression on BM iILC2s from Vav.G9a−/− mice (black line) and 
control G9afl/fl mice (dark gray; n = 5). The light gray shaded area represents the negative control (Ctrl). (D) ST2 and GATA3 expression in BM iILC2s from 
G9afl/fl or Vav.G9a−/− mice. Data are representative of two independent experiments (n = 2–3 per experiment). (E) Absolute numbers of BM ILC2s in Vav.
G9a−/− mice and control G9afl/fl mice after treatment with PBS or IL-33. Data are from three independent experiments (n = 5 for PBS and n = 11 for IL-33). 
(F) Reconstitution of mixed BM chimeras of Vav.G9a−/− BM and control G9afl/fl BM competed with CD45.1/2 BM and together injected into lethally irradiated 
CD45.1 mice was examined 8–12 wk after transplant. (G) Relative iILC2 chimerism normalized to splenic B cells. Data are from two of three independent 
experiments (n = 4–5 mice per experiment). (H) Frequencies of CLPs (CD45+ Lin− CD127+ Flt3+ α4β7−), α4β7+ lymphoid progenitors (αLP; CD45+ Lin− CD127+ 
Flt3− α4β7+), and ChILPs (CD45+ Lin− CD127+ Flt3− α4β7+ CD25− c-Kit+). Data are from three independent experiments (n = 7). ns, not significant. *, P < 0.05; 
Student’s t test. Errors bars indicate SEM.
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G9a regulates the ILC2-specific effector state by 
repressing ILC3-specific genes
We next used genome-wide expression analysis to identify 
the molecular signature of G9a-deficient ILC2s. We sorted 
CD45+ Lin− c-kitlow Sca-1high CD25+ ST2+ iILC2s from the 
BM of G9afl/fl or Vav.G9a−/− mice and expanded them in 
vitro for 10 d in the presence of IL-2, IL-7, and IL-25. Con-
sistent with our in vivo findings, in vitro expanded iILC2s 
from Vav.G9a−/− mice expressed lower levels of well char-
acterized ILC2-specific genes including Il1rl1, Crlf2, Il5, 
Il13, Areg (amphiregulin), Gata3, and Icos (inducible T cell 
co-stimulator; Fig. 4 A). Over 70% of the core ILC2 genes 
(Robinette et al., 2015) show reduced expression in the ab-
sence of G9a (Fig. 4 B and Table S1), suggesting that G9a 
is a central control point in ILC2 development. Strikingly, 
we found that expression of ILC3-associated genes such as 
Il1r1, Il23r, Rorc, Il17f, Il22, and Lta was significantly higher 
in ILC2s from Vav.G9a−/− mice (Fig. 4 A). Indeed, >80% of 
the core ILC3 genes were increased in G9a-deficient ILC2s 
(Fig. 4 B). These results demonstrate that G9a serves an im-
portant function in promoting ILC2 development while in-
hibiting the ILC3-associated gene expression program.
In the absence of G9a, we observed a reduction in the 
frequency of ILC2s producing IL-5, and the production of 
IL-17F was only seen in cultures of G9a-deficient ILC2s 
(Fig.  4 C). Critically, IL-17F–producing cells were distinct 
from IL-5–producing cells, suggesting that G9a specifically 
represses ILC3 differentiation in developing iILC2s. We 
found that ∼7.5% of the ST2− fraction of the Lin− c-kitlow 
Sca-1high CD25+ cells from the BM of Vav.G9a−/− mice were 
RORγt+, compared with <1% in the ST2+ fraction of either 
Vav.G9a−/− or G9afl/fl cells (Fig. 4 D), suggesting that loss of 
G9a in iILC2s leads to ectopic expression of ILC3-associ-
ated genes. Next, we examined whether transfer of iILC2s 
from Vav.G9a−/− mice into NOD-Scid Il2rg−/− (NSG) mice 
(Halim et al., 2012b) would result in the development of 
both mature ILC2s and mature ILC3s. We transferred 5,000 
iILC2s (CD45+ Lin− c-kitlow Sca-1high CD25+CD127+) iso-
lated from the BM of G9afl/fl or Vav.G9a−/− mice into NSG 
mice and analyzed the small intestine and lungs 3–4 wk 
later. We found that all of the ILCs in the small intestine 
of NSG mice that received iILC2s from G9afl/fl mice were 
mature ILC2s based on KLRG1 (killer cell lectin-like recep-
tor subfamily G member 1) expression (Hoyler et al., 2012), 
whereas G9a-deficient iILC2s gave rise primarily to ILC3s 
based on RORγt expression (Fig.  4 E). We found a simi-
lar result in the lungs with G9afl/fl iILC2s generating mature 
ILC2s, and G9a-deficient iILC2s were able to generate both 
mature ILC2s and ILC3s despite the fact that ILC3s are nor-
mally restricted from the lungs in the steady state (Fig. 4 E; 
Halim et al., 2012b). Therefore, G9a is required to repress the 
ILC3 potential of iILC2s.
Figure 2. G9a-deficient mice lack tissue ILC2s. (A) Frequencies of ILC2s in the mLN, lung, and VAT of G9afl/fl and Vav.G9a−/− mice. ICOS, inducible T cell 
co-stimulator. (B) Quantification of total ILC2s (mLN, n = 9–10; and lung, n = 6) or frequency of live CD45+ (VAT, n = 4). (C) Representative expression of 
ST2 in mature ILC2s from G9afl/fl (dark gray) and Vav.G9a−/− mice (black line). Light gray represents the negative control (Ctrl). *, P < 0.05; Student’s t test. 
Errors bars indicate SEM.
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Consistent with our results, we found a threefold in-
crease in the frequency of ILC3s in the Peyer’s patches and 
small intestinal lamina propria of Vav.G9a−/− mice compared 
with G9afl/fl controls (Fig.  4 F), demonstrating that G9a is 
required to limit the differentiation of ILC3s. However, it 
remained to be determined whether G9a is also required to 
repress the ILC3 gene program in terminally differentiated 
ILC2s. To test this directly, we treated G9afl/fl and Vav.G9a−/− 
mice with a short course of papain and isolated cells from 
the lungs, stimulated them ex vivo, and looked at cytokine 
production. We found increased production of IL-17A after 
stimulation of mature lung ILC2s, suggesting that repression 
of ILC3 cytokines in mature ILC2s requires G9a. We also 
saw a significant reduction in IL-13 production (Fig. 4 G), 
highlighting a role for G9a in promoting ILC2-dependent 
gene expression in mature ILC2s. It is noteworthy that unlike 
Gfi1-deficient mice, IL-17A–producing cells were mainly dis-
tinct from IL-13–producing cells, with only a few cells coex-
pressing the two cytokines. Thus, G9a is required to silence the 
ILC3 program in developing iILC2s as well as mature ILC2s.
G9a-dependent H3K9me2 is enriched at the 
promoters of ILC3 genes in ILC2s
Next, we cultured sorted iILC2s from the BM of WT mice in 
the presence of IL-2, IL-7, IL-25, and the G9a-specific meth-
yltransferase inhibitor UNC0638 (Vedadi et al., 2011). Simi-
lar to the phenotype of iILC2s derived from Vav.G9a−/− mice, 
inhibition of G9a methyltransferase activity in WT iILC2s 
resulted in reduced expression of Il5 and Il13, with a con-
comitant increase in expression of the ILC3-associated genes 
Rorc and Il17f (Fig. 5 A). Based on these results, we exam-
ined the levels of H3K9me2 at various ILC2- and ILC3-re-
Figure 3. G9a-deficient mice are protected from papain and HDM-induced lung eosinophilia. (A) G9afl/fl and Vav.G9a−/− mice were intranasally 
challenged with a short course of papain. Mice were sacrificed 24 h after the last challenge. Expression of Il5 and Il13 in lungs was measured by quanti-
tative RT-PCR. Quantification of eosinophils in the BAL of naive and papain-treated mice as determined by flow cytometry is shown. Data are from three 
independent experiments (n = 4–7 per experiment). (B) Rag.G9afl/fl mice and Rag.Vav.G9a−/− mice were intranasally challenged with a short course of papain. 
Mice were sacrificed 24 h after the last challenge. Quantification of eosinophils in the BAL was determined by flow cytometry. Data are from two inde-
pendent experiments (n = 4–7 per experiment). (C) Number of ILC2s in the lungs and eosinophils in the BAL were quantified after a long course of papain. 
Data are from two independent experiments (n = 3–7 per experiment). (D) Numbers of ILC2s in the lung and eosinophils in the BAL were quantified after 
administration of HDM antigen. (E) Expression of Il5 and Il13 in lungs was measured by quantitative RT-PCR. (F) The number of PAS+ goblet cells per field 
in the large airways was enumerated. (G) PAS-stained lung sections. Bars, 100 µm. (H) IL-5 and IL-13 production by equal numbers of ILC2s purified from 
the lungs of G9afl/fl or Vav.G9a−/− mice. The data shown are representative of four independent experiments (n = 3–6 per experiment). (D–G) Data are from 
three independent experiments with n = 4–9 per experiment. *, P < 0.05; Student’s t test. Errors bars indicate SEM.
G9a-dependent ILC development | Antignano et al.1158
lated gene loci in cytokine-expanded iILC2s from G9afl/fl and 
Vav.G9a−/− mice by chromatin immunoprecipitation (ChIP). 
We detected high levels of G9a-dependent H3K9me2 at the 
Il17f and Rorc promoters in iILC2s from G9afl/fl mice, con-
sistent with its lack of expression in ILC2s (Fig. 5 B). Despite 
reduced Il13 and Il5 expression in G9a-deficient ILC2s, we 
Figure 4. Loss of G9a in iILC2s results in an ILC3 phenotype. (A) RNA-Seq analysis of IL-2–, IL-7 –, and IL-25–expanded BM iILC2s showing differential 
of expression down-regulated genes (green) and up-regulated (red) in Vav.G9a−/− cells relative to control G9afl/fl cells. Data are from n = 3 mice per genotype. 
FPKM, fragments per kilobase of transcript per million mapped reads. (B) Heat maps of the expression of ILC2 and ILC3 core genes obtained from the RNA-
Seq data in A. (C) Intracellular expression of IL-17F and IL-5 from sorted and expanded BM iILC2s treated with PMA, ionomycin, and brefeldin A for 4 h. The 
numbers in the quadrants indicate percentage of cells in each. Data are representative of three independent experiments. (D) ST2 and RORγt expression in 
BM iILC2s from G9afl/fl or Vav.G9a−/− mice. Data are representative of two independent experiments (n = 2–3 per experiment). ns, not significant. *, P < 0.05; 
Student’s t test. Errors bars indicate SEM. (E) RORγt and KLRG1 expression on CD45.2+ Lin− CD90.2+ Sca1+ CD127+ cells isolated from of the small intestine 
(SI) and CD45.2+ Lin− CD90.2+ CD127+ cells isolated from the lungs of NSG mice 3–4 wk after transfer of iILC2s from G9afl/fl or Vav.G9a−/− mice. Data are 
representative of two independent experiments (n = 1–2 per experiment). (F) Frequencies of ILC3s (live CD45+ Lin− CD90.2+ RORγt+) in Peyer’s patches (PP) 
and small intestinal lamina propria of G9afl/fl or Vav.G9a−/− mice. Data are representative of n = 4 mice per genotype. LPL, lamina propria lymphocyte. (G) 
Intracellular expression of IL-17A and IL-13 from G9afl/fl- or Vav.G9a−/−-gated lung ILC2s. After a short course of papain, cells were treated with cell stimu-
lation cocktail (plus protein transport inhibitors) for 4 h. The numbers in the quadrants indicate the percentage of cells in each. The data are concatenated 
plots from three individual mice and are representative of two independent experiments (n = 3 per experiment). 
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found no difference in the levels of acetylated H3K9/14 
(H3K9/14Ac), an activating histone modification, at the 
promoters for Il13 or Il5 (Fig.  5 C); however, we did see 
reduced levels at the Gata3 promoter (Fig. 5 C), suggesting 
that ILC2 lineage identity is reduced in the absence of G9a. 
In addition, consistent with the heightened production of 
IL-17F by G9a-deficient iILC2s, we found increased levels 
of H3K9/14Ac at the Il17f and Rorc promoters (Fig. 5 C). 
Despite the importance of G9a-mediated H3K9me2 in the 
repression of ILC3 genes in ILC2s, we did not see any differ-
ences in G9a expression levels in ILC2s versus ILC3s in WT 
mice (unpublished data). Thus, G9a-dependent H3K9me2 
is associated with repression of the Il17f and Rorc loci in 
ILC2s, and the absence of G9a leads to increased epigenetic 
activation and expression of ILC3-associated genes.
These results define the first epigenetic regulatory 
mechanism that controls ILC development, differentiation, 
and function. G9a-dependent H3K9me2 is required for si-
lencing of ILC3-associated genes in iILC2s and suppression 
of ILC3 development. Further, G9a is required to promote 
expression of ILC2-associated genes in mature ILC2s. Inter-
estingly, a recent study demonstrated that ILCs from mice 
with a deletion in the transcription factor Gfi1 display de-
creased frequencies of ILC2s and dysregulated expression of 
ILC3-associated genes (Spooner et al., 2013), a phenotype 
similar to G9a-deficient ILC2s. As Gfi1 has been shown to 
directly interact with G9a (Duan et al., 2005), our results 
suggest that G9a–Gfi1 interactions may be critically im-
portant in the epigenetic regulation of ILC development. 
Collectively, the results presented here identify an additional 
level of regulation of ILC2/ILC3 development and sug-
gest that modulation of G9a activity may provide a novel 
therapeutic strategy to treat diseases associated with dys-
regulated ILC responses.
MAT ERI ALS AND MET HODS
Mice. Vav.G9a−/− mice and control G9afl/fl on a C57BL/6 
background, which have been previously described (Lehnertz 
et al., 2010), B6.SJL-PtprcaPepcb/BoyJ (CD45.1), and NSG 
mice were bred and maintained at the University of British 
Columbia Biomedical Research Centre. Rag.Vav.G9a−/− 
mice and Rag.G9afl/fl mice were generated by crossing 
Vav.G9a−/− mice and control G9afl/fl mice with Rag1−/− mice. 
All experiments were performed using sex-matched litter-
mates. All mice were maintained in a specific pathogen–free 
environment. All experiments were performed at the Univer-
sity of British Columbia according to institutional and Cana-
dian Council on Animal Care guidelines approved by the 
University of British Columbia Committee on Animal Care.
Cytokine administration. G9afl/fl and Vav.G9a−/− mice were 
given intraperitoneal injections of 500 ng IL-33 (eBiosci-
ence) on days 0, 1, 2, and 3 as previously described (Price et 
al., 2010). Mice were euthanized 24 h after the final injection, 
and BM was harvested and analyzed. 
BM chimeras. CD45.1 recipient mice were lethally irradiated 
with 10 Gy with an X-Rad (Precision X-Ray) and were re-
constituted by intravenous injection of BM from CD45.1/2 
mice mixed with either G9afl/fl or Vav.G9a−/− BM cells (2.5 × 
106 cells) to achieve an ∼50:50 chimera after stable reconsti-
tution. At least 8 wk after transplant, mice were euthanized, 
and BM and spleens were collected for analysis.
Lung inflammation models. For the short course of papain, 
G9afl/fl and Vav.G9a−/− mice were anesthetized, followed by 
intranasal instillation of 10 µg papain in 40 µl PBS on days 0, 
1, and 2. Mice were sacrificed on day 3, and BAL fluid and 
lungs were collected and analyzed. Intracellular cytokines 
Figure 5. Altered effector state is G9a methyltransferase dependent. (A) Quantitative RT-PCR analysis of the indicated genes from sorted BM iILC2s 
expanded for 10 d in IL-2, IL-7, and IL-25 in the presence or absence of UNC0638. Data are from two independent experiments (n = 6–7 per treatment). 
(B and C) BM iILC2s expanded for 14 d in IL-2, IL-7, and IL-25 and processed for ChIP analysis using antibodies specific for H3K9me2 (B) or H3K9/14Ac 
(C). Quantitative PCR was performed using primers for the promoters of the specified genes. Data shown are from three to five independent experiments 
performed in triplicate. *, P < 0.05; Student’s t test. Errors bars indicate SEM.
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were detected after 4 h of stimulation with cell stimulation 
cocktail (plus protein transport inhibitors; eBioscience) using 
an intracellular fixation and permeabilization buffer set (eBio-
science) according to the manufacturer’s protocol with the 
antibodies IL-13 (eBio13A) and IL-17A (eBio17B7). Live 
cells were identified using fixable viability dye (eFluor 506; 
eBioscience). For the long course of papain, G9afl/fl and Vav.
G9a−/− mice were anesthetized and then sensitized with pa-
pain (10 µg in 40 µl) by intranasal instillation on days 0, 3, and 
6. Mice were rechallenged on day 14, and BAL fluid and 
lungs were collected on day 15. HDM (Dermatophagoides 
pteronyssinus)-mediated allergic inflammation was induced 
in G9afl/fl and Vav.G9a−/− mice by intranasal instillation with 
100 µg HDM antigen (Greer Laboratories) on days 0, 1, and 
2 and 25 µg on days 13, 14, 15, 16, and 17. Mice were sacri-
ficed 24 h after the final challenge. BAL cells were enumer-
ated and differentiated by flow cytometry with antibodies to 
CD3e (145-2C11), CD11c (N418), CD45 (I3/2), B220 
(RA3-6B2), Siglec-F (E50-2440), and Ly6B (7/4).
Histology. Lung lobes were fixed in 10% buffered forma-
lin solution and embedded into paraffin blocks. 5-µm sec-
tions were stained with periodic acid-Schiff (PAS). Airways 
were assessed for PAS staining as an indication of mucus 
hyperproduction. PAS+ cells in the airways in each lung 
section were quantified.
Cell culture. iILC2s (live CD45+ Lin− cKit− Sca1+ CD25+ 
ST2+) were sorted from the BM of naive G9afl/fl and Vav.
G9a−/− mice. Approximately 5,000 cells were cultured in 
200 µl IMDM containing 10% FCS, penicillin-streptomycin, 
and 150 µM monothioglycerol with 50 ng/ml rIL-2, 10 ng/
ml rIL-7, and 100 ng/ml rIL-25. Cells were split and diluted 
1:2 with fresh cytokine-containing media on day 3 and every 
other day thereafter. When used, the G9a inhibitor UNC0638 
was added to cytokine-containing media at 0.5 µM. Live cells 
were counted by trypan blue exclusion. Intracellular cyto-
kines were detected after 4 h of stimulation with 50 ng/ml 
PMA and 750 µg/ml ionomycin in the presence of 10 µg/ml 
brefeldin A using an intracellular fixation and permeabiliza-
tion buffer set (eBioscience) according to the manufacturer’s 
protocol with the antibodies IL-5 (TRFK5) and IL-17F 
(eBio18F10). Live cells were identified using eFluor 506 
fixable viability dye. 
RNA sequencing. ILC2s were sorted from BM and expanded 
in IL-2, IL-7, and IL-25 for 10 d. Cells were harvested and 
total RNA was extracted using an RNeasy Mini kit accord-
ing to manufacturer’s instructions (QIA GEN). Approximately 
500 ng RNA was prepared with an mRNA kit (Truseq 
Stranded; Illumina) and sequenced on a MiSeq paired-end run 
(75 × 75; v3; Illumina). Samples were aligned to the 10-mm 
transcript reference using TopHat2, and differential expres-
sion was assessed using Cufflinks. The heat map of ILC2 and 
ILC3 core genes expressed in G9afl/fl and Vav.G9a−/− iILC2s 
were generated using the open source R and VisR platforms 
(Younesy et al., 2015). Data are available through NCBI Bio-
Project database accession no. PRJ NA313104. 
Quantitative real-time PCR (RT-PCR). RNA was isolated 
from expanded BM ILC2s using an RNeasy Mini kit accord-
ing to the manufacturer’s instructions (QIA GEN). Lung tissue 
was homogenized using a TissueLyser (QIA GEN). RNA was 
extracted using TRIzol (Invitrogen) and reverse transcribed 
with a high-capacity cDNA synthesis kit (Thermo Fisher 
Scientific), and gene expression was analyzed by quantitative 
RT-PCR with SYBR green chemistry (KAPA Biosystems) 
on an RT-PCR system (7900 Fast; Applied Biosystems). The 
primers used were obtained from QIA GEN or synthesized de 
novo: Il5 forward, 5′-GAT GAG GCT TCC TGT CCC TAC 
TC-3′ and reverse, 5′-TCG CCA CAC TTC TCT TTT TGG-
3′; Il13 forward, 5′-CCT GGC TCT TGC TTG CCTT-3′ and 
reverse, 5′-GGT CTT GTG TGA TGT TGC TCA-3′; Il17f 
forward, 5′-TGC TAC TGT TGA TGT TGG GAC-3′ and re-
verse, 5′-AAT GCC CTG GTT TTG GTT GAA-3′; Rorc for-
ward, 5′-TCC ACT ACG GGG TTA TCA CCT-3′ and reverse, 
5′-AGT AGG CCA CAT TAC ACT GCT-3′; and Actb forward, 
5′-GGC TGT ATT CCC CTC CAT CG-3′ and reverse, 5′-
CCA GTT GGT AAC AAT GCC ATGT-3′.
ChIP. ILC2s were sorted from BM and expanded in IL-2, 
IL-7, and IL-25 for 14 d. ChIP for H3K9me2 and H3K9/14Ac 
was conducted as previously described (Dong et al., 2008) 
using 1 µg of antibody specific to H3K9me2 (ab1220; Abcam) 
or H3K9/14Ac (06-599; EMD Millipore). After washing, 
elution, and reversion of cross-links, the DNA was isolated 
and used in quantitative PCR reactions on an RT-PCR sys-
tem (ABI 7900 Fast). Data are presented as the ratio of immu-
noprecipitated to input cycle threshold (CT)  values. The 
primers used for PCR analysis were: Il5 promoter forward, 
5′-AAG TCT AGC TAC CGC CAA TA-3′ and reverse, 5′-
AGC AAA GGT GAG TTC AAT CT-3′; Il13 promoter for-
ward, 5′-GGG CAG GTG AGT ATC AGT CTA-3′ and reverse, 
5′-GTC TAT ATC CCT CCC ACT CGT-3′; Il17f promoter 
forward, 5′-GGG AAT CAA AGG GGG ACC CTAA-3′ and 
reverse, 5′-AAA GCA GAA CCC ACA CGC AGAG-3′; Gata3 
promoter forward, 5′-CGT ATA TGA TGA GTC TTC TCT 
GGG ACT TG-3′ and reverse, 5′-AAA TCT CAG AAC ACA 
CAC ATT TCC AGG-3′; and Rorc promotor forward, 5′-
ATT CCA TGA GGG CTT GCCT-3′ and reverse, 5′-ACC 
TGT CAT CAG CCT CCC ATA-3′. 
Preparation of cell suspension. BM cells were isolated by 
flushing femurs and tibias with a 26-G needle though a 
70-µm strainer. Lungs were minced and digested in 200 U/ml 
collagenase IV (Sigma-Aldrich) for 45 min at 37°C and 
passed through a 70-µm cell strainer. RBCs were lysed, and 
leukocytes were enriched using a Percoll (Sigma-Aldrich) 
separation. mLNs and Peyer’s patches were passed through a 
70-µm cell strainer to form single-cell suspensions. Small 
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intestine lamina propria cells were isolated by digestion in 0.5 
mg/ml collagenase/dispase for 30 min after removal of intes-
tinal epithelial cells. Leukocytes were enriched using a stan-
dard Percoll separation method.
Antibodies and flow cytometry. Staining and antibody dilu-
tions were prepared in PBS containing 2% FCS, 2 mM EDTA, 
and 0.05% sodium azide. Samples were first blocked in buffer 
containing 5 µg/ml anti-CD16/32 (2.4G2) and 2% rat serum 
to block nonspecific antibody binding. Viable cells were iden-
tified using the eFluor 506 fixable viability dye. The following 
antibodies were used to identify ILCs: pan-CD45 (I3/2), lin-
eage markers  (CD3e [145-2C11 and KT3], CD5 [53-7.3], 
CD4 [GK1.5; not used when staining for ILC3s], CD8 
[53.67], CD11c [N418], CD11b [M1/70], CD19 [1D3], 
NK1.1 [PK136], Gr1 [RB6-8C5], and Ter119 [TER-119]), 
CD25 (PC61.5), CD127 (SB/199), Sca1 (D7), cKit (ACK2), 
ST2 (RMST2-2), CD90.2 (53-2.1), KLRG1 (2F1), ICOS 
(7E.17G9), GATA3 (TWAJ), and RORγt (B2D). Additional 
antibodies used include IL-17RB (MUNC33), CD45.1 
(A20), and CD45.2 (104).
NSG adoptive transfers. NSG-recipient mice were injected 
intravenously with 5,000 FACS-purified BM iILC2s (CD45+ 
Lin− c-kitlow Sca-1high CD25+ CD127+) from Vav.G9a−/− 
mice and control G9afl/fl. After 3–4 wk, small intestinal lamina 
propria cells and lung cells were isolated and evaluated for the 
presence of ILC2s and ILC3s.
Statistics. Results represent the mean ± SEM. Statisti-
cal significance was determined by Student’s t test using 
Prism 5.0 (GraphPad Software). A p-value <0.05 was 
considered significant.
Online supplemental material. Table S1 is a list of core ILC2 
and ILC3 genes (Robinette et al., 2015) compared with 
control and G9a-deficient iILC2s. Online supplemental 
material is available at http ://www .jem .org /cgi /content 
/full /jem .20151646 /DC1.
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